STOCK TITAN
  1. Home
  2. Financials
  3. BNTX
  4. EPS (Diluted)

BioNTech (BNTX) EPS by Year

BNTX

BioNTech lost $5.52 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters BioNTech has filed alongside them.

FY2025 annual
EPS (Diluted) -$5.52
YoY n/m
Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

BNTX EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
EPS (Diluted)-$5.52n/m-$2.87-167.7%$4.24-89.5%$40.41-9.9%$44.85+61007.9%$0.07n/m-$0.95N/AN/A

BNTX EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ4'2520-FQ4'2420-FQ4'2320-FQ4'2220-FQ4'2120-FQ4'2020-FQ4'1920-FQ4'1820-F
EPS (Diluted)N/AN/AN/AN/AN/AN/AN/AN/A

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More BioNTech financials

Frequently Asked Questions

What was BioNTech's diluted earnings per share in fiscal year 2025?

BioNTech lost $5.52 per diluted share in fiscal year 2025.

How fast is BioNTech's diluted earnings per share growing?

BioNTech (BNTX) reported a loss of $2.87 per diluted share in fiscal year 2024 and a loss of $5.52 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

What does diluted earnings per share mean on a financial statement?

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what BioNTech (BNTX) reported on that line in every period on record.